https://www.selleckchem.com/pr....oducts/daratumumab.h
3%) and body weight (1.3%-2.5% decrease vs. +0.8% with placebo; 95% CIs 100 μg -3.4%, -0.8%; 200 μg -4.7%, -2.0%; 300 μg -4.6%, -2.1%; placebo -2.1%, 0.4%). The most common adverse events with cotadutide were mild gastrointestinal symptoms with no serious adverse events. Increased pulse rate with cotadutide versus placebo is consistent with GLP-1 monoagonists. Once-daily cotadutide was effective and well tolerated up to 300 μg in overweight Japanese patients with T2D. Further evaluation in Asian populations is warranted. Once-daily
Like
Comment
Share
